Volume 6.41 | Oct 20

Hematopoiesis News 6.41 October 20, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
The CNIO Opens Up a New Avenue for Combating the Deterioration in Blood Stem Cells Caused by Aging Chemotherapy and Radiation Therapy
Researchers shed light on the molecular mechanisms of aging of the stem cells responsible for regenerating blood cells and opens up a new avenue for reducing their progressive functional decline with age. [Press release from the Spanish National Cancer Research Center (CNIO) discussing online publication in Nature Communications] Press Release | Full Article
SmartDish™ with STEMgrid™-6 for Accurate Counting of Hematopoietic CFU Assays
PUBLICATIONS (Ranked by impact factor of the journal)
Loss of Tifab, a del(5q) MDS Gene, Alters Hematopoiesis through Derepression of Toll-Like Receptor-TRAF6 Signaling
A subset of mice transplanted with Tifab knockout (KO) hematopoietic stem/progenitor cells (HSPCs) developed a bone marrow failure with neutrophil dysplasia and cytopenia. In competitive transplants, Tifab KO HSPCs are out-competed by wild-type cells, suggesting a cell-intrinsic defect. [J Exp Med] Abstract

Shp2 and Pten Have Antagonistic Roles in Myeloproliferation but Cooperate to Promote Erythropoiesis in Mammals
Researchers demonstrated that ablating SH2-containing tyrosine phosphatase (Shp2) suppressed the myeloproliferative effect of phosphatase and tensin homolog (Pten) loss, indicating directly opposing functions between pathways regulated by these two enzymes. [Proc Natl Acad Sci USA] Abstract

Reconstructing the In Vivo Dynamics of Hematopoietic Stem Cells from Telomere Length Distributions
Scientists investigated the in vivo patterns of stem cell divisions in the human hematopoietic system throughout life. They found an increasing stem cell pool during childhood and adolescence and an approximately maintained stem cell population in adults. [Elife] Abstract | Full Article

CD150 Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1
Researchers demonstrated that SIRT1 homozygous knockout substantially reduces CD150 side population chronic myeloid leukemia (CML) leukemia stem cells (LSCs), and compromises the maintenance of CML LSCs in the BALB/c model. [Stem Cells] Abstract

Effects of Scorpion Venom Peptide B5 on Hematopoietic Recovery in Irradiated Mice and the Primary Mechanisms
The authors investigated the effects of scorpion venom peptide-B5 on hematopoietic recovery in mice after total body irradiation at a dose of 7.5Gy and 6Gy and to explore the possible primary mechanisms. [Sci Rep] Full Article

Progressive Chromatin Condensation and H3K9 Methylation Regulate the Differentiation of Embryonic and Hematopoietic Stem Cells
Investigators tested the hypothesis that global chromatin organization affects the lineage potential of stem cells and that manipulation of chromatin dynamics influences stem cell function. Using nuclease sensitivity assays, they found a progressive decrease in chromatin digestion among pluripotent embryonic stem cells, multipotent hematopoietic stem cells, and mature hematopoietic cells. [Stem Cell Reports]
Full Article | Graphical Abstract

Different Motile Behaviors of Human Hematopoietic Stem versus Progenitor Cells at the Osteoblastic Niche
Using a xenotransplantation model and intravital imaging, scientists demonstrated that human hematopoietic stem cells (HSCs) display distinct motile behaviors to their hematopoietic progenitor cell (HPC) counterparts, and the same pattern can be found between mouse HSCs and HPCs. [Stem Cell Reports] Full Article


Long-Term Outcome of Patients with Newly Diagnosed Chronic Myeloid Leukemia-A Randomized Comparison of Stem Cell Transplantation with Drug Treatment
This prospective randomized chronic myeloid leukemia (CML)-study IIIA recruited 669 patients with newly diagnosed CML. Of these, 427 patients were considered eligible for hematopoietic stem cell transplantation and were randomized by availability of a matched family donor between primary HSCT and best available drug treatment. [Leukemia] Full Article

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL. MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes. [Clin Cancer Res] Abstract

It all starts with the right cells! Order fresh and frozen primary cells now.
Wnt/β-Catenin Signaling in Bone Marrow Niche
The authors review the role of the Wnt/β-catenin pathway in the bone marrow niche and its importance in stem cells. [Cell Tissue Res] Abstract

Environments of Hematopoiesis and B-Lymphopoiesis in Fetal Liver
The authors review recent developments and the current contributions on the research on blood cell development. [Clin Exp Rheumatol] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Register for the CAR-T Summit 2015!
Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL)
Pfizer Inc. announced that investigational antibody-drug conjugate inotuzumab ozogamicin received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for ALL. [Pfizer Inc.] Press Release

Kiadis Pharma Announces Enrolment of First Patient in Its Repeat-Dosing Phase II Clinical Trial with ATIR101™
Kiadis Pharma N.V. announced that the first patient has been enrolled into its repeat-dosing Phase II clinical trial, CR-AIR-008, with its lead product ATIR101™. [Kiadis Pharma N.V.] Press Release

From our sponsor: Isolate human immune cells in as little as 8 minutes with EasySep™ Request a sample.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Innovation and Biomarkers in Cancer Drug Development (IBCD)
December 3-4, 2015
Brussels, Belgium

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

NEW Postdoctoral Research Fellow – Medicinal Chemistry for Cancer Drug Discovery (University of Michigan)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Technician – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – iPSC Models of Hematologic Disorders (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Leukemia Stem Cell Biology (Lund University)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Postdoctoral Positions – Cancer and Developmental Biology (North Carolina Central University)

Assistant Professor – Stem Cell Biology (University of South Carolina)

Postdoctoral Position – Hematology and Immunology (University of Liege)

Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us